Lupin Limited
LUPIN.NS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$894.58B
Close$
$4318.08
Infinity% upside
Current Fair Value
Infinity% upsideUndervalued by Infinity% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $894.58 Billion |
|---|---|
| Enterprise Value | - |
| Annual dividend | $18.00 |
| Dividend yield | 0.92% |
| Earnings per Share | $116.75 |
| Beta | 0.18 |
| Outstanding Shares | 457,189,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 16.17 |
|---|---|
| PEG | 100.57 |
| Price to Sales | 0.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$29.19
Consensus analyst estimateRevenue Estimate
$79.08 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$24.65
Consensus analyst estimateRevenue Estimate
$77.03 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Lupin Limited
24,006 employees
CEO: Vinita D. Gupta
Lupin Limited functions as a global pharmaceutical enterprise, dedicated to the research, development, production, marketing, and distribution of a broad spectrum of products. These include both proprietary and generic drug formulations,...